Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.

about

Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.

Item

http://www.wikidata.org/entity/Q40441376

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Influence of CYP3A5 genetic va ...... after cardiac transplantation.

@en

type

Item

label

Influence of CYP3A5 genetic va ...... after cardiac transplantation.

@en

prefLabel

Influence of CYP3A5 genetic va ...... after cardiac transplantation.

@en

P1476

Influence of CYP3A5 genetic va ...... after cardiac transplantation

@en

P2093

Georg M Fiedler

http://www.w3.org/2001/XMLSchema#string

Johanna Sistonen

http://www.w3.org/2001/XMLSchema#string

Lars Englberger

http://www.w3.org/2001/XMLSchema#string

Paul Mohacsi

http://www.w3.org/2001/XMLSchema#string

Raschid Setoud

http://www.w3.org/2001/XMLSchema#string

Vilborg Sigurdardottir

http://www.w3.org/2001/XMLSchema#string

P2860

New equations to estimate GFR in children with CKD

A new equation to estimate glomerular filtration rate

Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows

Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.

Clinical pharmacokinetics of everolimus.

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.

Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

P304

1213-1220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CTR.12653

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dorothea Lesche

Carlo R Largiadèr

P577

2015-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26458301

http://www.w3.org/2001/XMLSchema#string